Dibekacin Meiji Mechanism of Action

Dibekacin Meiji injection has potent bactericidal activity against gram-positive and -negative bacteria including Pseudomonas aeruginosa, Proteus sp, Klebsiella pneumoniae and multi-resistant strains of Escherichia coli and Staphylococci.
Therapeutic effect of Dibekacin Meiji injection has been confirmed in a large scale of clinical trials.
Dibekacin Meiji injection has the following characteristics: Bactericidal in its action against both gram-positive and gram-negative bacteria; produces therapeutic effect against infections caused by Pseudomonas aeruginosa and Proteus sp; also effective against infections due to Escherichia coli, Klebsiella pneumoniae and Staphylococci that have acquired multi-resistance to other drugs; rapidly absorbed into the blood and diffuses into the kidney and lung in high concentration after IM injection. It is excreted into the urine in active, unchanged form in high concentration.
Microbiology: Dibekacin exhibits strong antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and Proteus sp and against gram-positive bacteria as well. The MIC of Dibekacin Meiji injection against major pathogenic organisms is given as follows: See Table 1.


Click on icon to see table/diagram/image


Pharmacokinetics: Absorption and Excretion: A single IM injection of 50 mg and 100 mg (potency) produces peak blood concentrations of 5 mcg/mL and 7 mcg/mL around 30 min after injection. About 70-80% of the given dose is excreted into the urine within the first 8 hrs.